Cisplatin-Loaded Implant Efficacy in Sarcoma 180 Tumor-Bearing Mice

Cisplatin-loaded PLGA implants achieved a mean drug content of 37.7% ± 0.5% (w/w) and demonstrated sustained drug release. The study, authored by Li Gao of Ningbo University, evaluated antitumor efficacy and systemic toxicity reduction via continuous intratumoral chemotherapy in mice. Results showed the implants effectively inhibited tumor growth and reduced dose-related side effects compared to intravenous injection.

Use Cases

• Modeling drug release kinetics based on in vitro and in vivo release profiles mentioned in the description
• Evaluating tumor suppression rates based on varying implant doses described in the study
• Comparing systemic toxicity levels between intratumoral implantation and intravenous injection methods detailed in the research

Strengths

• Mean drug content of the tested implants is precisely quantified at 37.7% ± 0.5% (w/w)
• Study includes both in vitro and in vivo drug release profile characterizations
• Antitumor efficacy is evaluated in a specific preclinical model (sarcoma 180 tumor-bearing mice)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Last update date is unknown; freshness unverified

Provenance

Source

Li Gao, Ningbo University

Collection Method

Experimental study involving preparation of PLGA-based cisplatin-loaded implants and evaluation in a mouse model.